FDA clears SkinStylus SteriLock for periorbital wrinkles across all skin types

The FDA has cleared the SkinStylus SteriLock MicroSystem for the treatment of periorbital wrinkles in adults aged 22 and older, a decision that allows providers to target the delicate eye area across all Fitzpatrick skin types I through VI. With this clearance, the Class II medical device becomes the only microneedling system on the market cleared for three distinct indications: periorbital wrinkles, facial acne scars, and abdominal scars.

The clinical data behind this clearance, which was presented at the 2026 SCALE meeting, showed statistically and clinically meaningful improvements in periorbital wrinkles. For your practice, this clearance resolves a common clinical limitation, as many energy-based and microneedling treatments carry safety restrictions for darker skin types or require extreme caution around the orbit.

The business context is also shifting. Data from Guidepoint Qsight and NewBeauty Beauty Engine shows the microneedling market grew 33% year-over-year in 2025, reaching approximately US$330 million in US consumer spending. SkinHealth Systems is positioning the device to capture more of this demand across its footprint of more than 3,400 U.S. aesthetics locations.

If you already own the SkinStylus, you can immediately update your clinical protocols and marketing to include periorbital treatments for any patient. If you are shopping for a microneedling device, this triple clearance reduces your compliance risk by providing on-label coverage for the face, eyes, and body.

Source: Dermatology Times, https://www.dermatologytimes.com/view/icymi-skinstylus-gains-fda-clearance-for-periorbital-wrinkles-across-all-fitzpatrick-skin-types